Skip to main content
StemCell Longevita

Orthopaedics

Is it reasonable to try MSC therapy before a knee replacement?

Written by
StemCell Longevita Editorial Team
Medically reviewed by
Professor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
Last reviewed
Next scheduled review

How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards

For some patients with moderate knee osteoarthritis it is a defensible step; for advanced bone-on-bone disease it usually is not. Here is how the line is drawn.

Medically reviewed by:
Prof. Dr. Erdal Karaöz, PhD
Last reviewed:
Next review:

The short answer

If your cartilage loss is moderate, your pain is mechanical rather than constant, and surgery is being deferred for age or fitness reasons, an intra-articular MSC injection is a reasonable trial with published human evidence behind it. If your joint space is already gone, the honest answer is that no injection rebuilds it and arthroplasty remains the treatment with the strongest outcomes.

Who this decision applies to

Usually appropriate to discuss

  • Kellgren–Lawrence grade 2–3 osteoarthritis confirmed on recent imaging
  • Pain that varies with load and activity rather than being constant at rest
  • Physiotherapy and weight management already tried for at least three months
  • Surgery deferred or declined for age, comorbidity or personal reasons

Not appropriate right now

  • Grade 4 bone-on-bone disease with mechanical locking or deformity
  • Active joint infection or unexplained effusion
  • Inflammatory arthritis that has never been assessed by a rheumatologist
  • An expectation that cartilage will be regrown to a younger state

Evidence at a glance

The same five questions we ask of every indication, answered for this one.

Evidence maturity for MSC therapy before knee replacement
QuestionAnswerWhat that means here
Human studies published?YesMultiple published human trials of intra-articular MSCs in knee osteoarthritis.
Randomised controlled trials?YesRandomised and placebo-controlled studies exist, though most are small and single-centre.
Objective outcome measures?YesWOMAC, VAS pain and MRI cartilage measures are reported across studies.
Long-term follow-up (≥12 months)?PartlyTwelve- and 24-month follow-up is published; multi-year data remain limited.
Approved as a routine therapy?NoNot an approved routine therapy; it does not replace arthroplasty where arthroplasty is indicated.

How these judgements are made: How we evaluate evidence · Editorial standards · Conflict-of-interest disclosure.

Options compared, including doing nothing

Realistic options for MSC therapy before knee replacement
OptionWhat it can realistically doMain trade-off
Continue conservative careMeaningful pain control for many grade 2 kneesDoes not change structural progression
Intra-articular MSC therapyPain and function improvement reported at 6–12 months in trial populationsNot curative; response varies and is not guaranteed
Corticosteroid or hyaluronic acid injectionShort-term relief, widely available and cheapEffect typically measured in weeks to months
Total knee arthroplastyThe most reliable outcome for advanced diseaseMajor surgery, recovery time, implant lifespan
Do nothing for nowReasonable if symptoms are tolerable and stableDeconditioning and weight gain worsen the joint over time

How the decision is made in practice

  1. We ask for weight-bearing X-rays taken within the last twelve months, plus MRI where available.
  2. We grade the joint and check whether the pain pattern matches the imaging; mismatches are investigated before anything is offered.
  3. We review what has already been tried, because untried physiotherapy is treated as a missing step, not a failed one.
  4. We state the realistic ceiling of benefit for your grade, in plain numbers, before cost is discussed.
  5. If a trial is agreed, outcome measures are recorded before treatment and repeated at three, six and twelve months.

When we decline, and why

  • Grade 4 disease where arthroplasty is clearly the better-evidenced option
  • Patients seeking to avoid a surgery their own surgeon has recommended for structural reasons
  • Uncontrolled diabetes, active infection or anticoagulation that makes injection unsafe
  • Any request for a guaranteed outcome

Declining is a normal outcome of assessment, not a failure of it. See how candidacy and redirection work.

Questions worth asking any clinic

  • What grade is my osteoarthritis, and what does the evidence show at that grade specifically?
  • Which outcome measures will you record before and after, and will I receive them in writing?
  • What is the cell type, dose and release-testing profile of the product being used?
  • What happens, clinically and financially, if there is no response at six months?

Frequently asked questions

No published human trial has shown reconstruction of a worn joint surface to a younger state. What trials do report is reduced pain and improved function over 6 to 12 months in selected patients, with some studies also reporting slower cartilage loss on MRI. Any clinic promising regrown cartilage is going beyond the evidence.

Published follow-up most often runs to twelve or twenty-four months, and reported benefit tends to decline gradually rather than stop abruptly. Because multi-year data are limited, we describe this as a trial with a measurable review point rather than a permanent solution.

An intra-articular injection does not preclude later arthroplasty. Where surgery is already clearly indicated, we say so rather than delaying it, because delay in advanced disease can make the eventual operation harder.

It depends on grade, body weight and response at the three-month review. We plan a single treatment first and only discuss repeat dosing if the recorded outcome measures justify it.

Sources

  1. mesenchymal stem cells knee osteoarthritis randomized trial — Randomised human trials of intra-articular MSCs in knee OA.
  2. umbilical cord mesenchymal stromal cells knee osteoarthritis WOMAC — Umbilical-cord-derived MSC studies reporting WOMAC outcomes.
  3. mesenchymal stromal cells knee osteoarthritis — Registered trials, including those still recruiting.

Citation practice and source hierarchy: How we evaluate evidence.

Related clinical questions

Want this reviewed for your own case?

Send your diagnosis, imaging and medication list. If the answer is no, we will say so and explain why.

Request a medical review · Check candidacy in 6 questions

How to cite this page

This page's evidence table is published under CC BY 4.0. Reuse it with attribution and a link back.

How to cite this page
StyleCitation
APAStemCell Longevita. (2026). Is it reasonable to try MSC therapy before a knee replacement?. StemCell Longevita. https://stemcelllongevita.com/clinical-decisions/knee-osteoarthritis-msc-before-replacement
VancouverStemCell Longevita. Is it reasonable to try MSC therapy before a knee replacement? [Internet]. Istanbul: StemCell Longevita; 2026 [cited 2026-08-23]. Available from: https://stemcelllongevita.com/clinical-decisions/knee-osteoarthritis-msc-before-replacement

BibTeX:

@techreport{longevita_knee_osteoarthritis_msc_before_replacement_2026,
  title       = {Is it reasonable to try MSC therapy before a knee replacement?},
  author      = {{StemCell Longevita}},
  institution = {StemCell Longevita},
  year        = {2026},
  url         = {https://stemcelllongevita.com/clinical-decisions/knee-osteoarthritis-msc-before-replacement},
  urldate     = {2026-08-23}
}

Structured data: The evidence table on this page is also published as a machine-readable dataset descriptor. /cite

Related pages